feedback

Course Director

Harry P. Erba, MD, PhD
Harry P. Erba, MD, PhD

University of Alabama at Birmingham
Birmingham, Alabama

Faculty

Naval Daver
Naval Daver, MD

The University of Texas MD Anderson Cancer Center
Houston, Texas

Amir T. Fathi
Amir T. Fathi, MD

Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Michael R. Savona
Michael R. Savona, MD

Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Stephen A. Strickland
Stephen A. Strickland, MD, MSCI

Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:2.5 Credits
Release Date:2018-Jan-30
Expiration Date:2019-Jan-29
Estimated Time for Completion:150 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, based on a live CME-certified symposium held at the 2017 meeting of the American Society of Hematology (ASH), experts in acute myeloid leukemia (AML) discuss modern AML treatment and illustrate how professionals can navigate an increasingly complex therapeutic landscape and effectively leverage the potency of newer agents across a variety of AML patient presentations—including those with FLT3- or IDH-mutant disease, the elderly, those with secondary AML, or those eligible for clinical trial–based treatment with antibodies or immunotherapy. Experience a deep dive into the science that is driving the rapidly emerging new era in AML patient care.

Upon completion of this activity, participants should be better able to:
  • Cite the clinical implications of cytogenetics, mutation status, older age, and other baseline factors for acute myeloid leukemia (AML) management
  • Summarize efficacy and safety evidence on novel therapeutics in AML, including newer targeted, cytotoxic, and antibody-based strategies, in a range of patient populations
  • Develop active, personalized regimens with novel components for patients with newly diagnosed or relapsed/refractory AML
  • Manage safety considerations in patients with AML receiving treatment with novel therapeutics

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, medical oncologists, and other clinicians involved in the management of patients with AML.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: January 30, 2018 - January 29, 2019
Time to Complete: 150 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Harry P. Erba, MD, PhD
Albert F. LoBuglio Endowed Chair for Translational Cancer Research
Chair, SWOG Leukemia Committee
Professor, Internal Medicine
University of Alabama at Birmingham
Division of Hematology/Oncology
Birmingham, Alabama

Harry P. Erba, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.; Celgene Corporation; Daiichi Sankyo Company, Limited; ImmunoGen, Inc.; Incyte Corporation; Jazz Pharmaceuticals; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; Ono Pharmaceutical, Co., Ltd.; and Seattle Genetics, Inc.
Grant/Research Support from Agios, Inc.; Amgen Inc.; Astellas Pharma US, Inc.; Daiichi Sankyo Company, Limited; ImmunoGen, Inc.; Janssen Pharmaceuticals, Inc.; Juno Therapeutics; Millennium Pharmaceuticals/Takeda Pharmaceutical; and Seattle Genetics, Inc.
Speakers Bureau participant with Celgene Corporation; Incyte Corporation; and Novartis Pharmaceuticals Corporation.
Other Financial or Material Support from Celgene Corporation, Chair, Data and Safety Monitoring Board and GlycoMimetics, Inc., Chair, Scientific Steering Committee.
Harry P. Erba, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: next-generation epigenetic therapies and targated agents, including Bcl-2 inhibitors, XPO1 inhibitors, and other targeted agents in development for AML.

Faculty

Naval Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Incyte Corporation; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; and Sunesis Pharmaceuticals, Inc.
Grant/Research Support from Bristol-Myers Squibb; Incyte Corporation; Kiromic; Pfizer Inc.; and Sunesis Pharmaceuticals, Inc.
Naval Daver, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immunotherapy in AML, including PD-1 ihibitors and bispecific antibodies.

Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Amgen Inc.; Celgene Corporation; MedImmune; and Seattle Genetics.
Advisory Board for Agios, Inc.
Amir T. Fathi, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: novel antibody-based therapies in AML, including those targeting CD33, CD45, CD123, and other antigen targets.

Michael R. Savona, MD
Director of Hematology Research
Associate Professor of Medicine
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Michael R. Savona, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Astex Therapeutics; Incyte Corporation; Sunesis Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and TG Therapeutics, Inc.
Advisory Board for Astex Therapeutics; Incyte Corporation; Karyopharm Therapeutics; and TG Therapeutics, Inc.
Other Financial or Material Support from Celgene Corporation and Gilead Sciences, Inc., Data and Safety Monitoring Board. Karyopharm Therapeutics in the form of equity.
Michael R. Savona, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: next-generation IDH1/2 inhibitors in the management of AML.

Stephen A. Strickland, MD, MSCI
Hematology Clinical Service Line Chief
Clinical Director, Acute Leukemia
Division of Hematology/Oncology
Assistant Professor of Medicine
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Stephen A. Strickland, MD, MSCI, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma US, Inc.
Grant/Research Support from Sunesis Pharmaceuticals, Inc.
Advisory Board for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Tolero Pharmaceuticals, Inc.
Stephen A. Strickland, MD, MSCI, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: next-generation FLT3 inhibitors in the management of AML.

CME Reviewer

Vishwanath Sathyanarayanan, MD, DM
Apollo Hospitals
Bangalore, Karnataka, India

Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Agios, Astellas Scientific and Medical Affairs, Inc., Celgene Corporation, and Jazz Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.